Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + lymphokine-activated killer cells
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intracavitary
01
Overview
Aldesleukin + lymphokine-activated killer (LAK) cells is an investigational combination immunotherapy regimen evaluated by Weill Medical College of Cornell University for the treatment of malignant gliomas. Aldesleukin is a recombinant form of interleukin-2 (IL-2) that acts as a potent T-cell growth factor and activator of natural killer (NK) cells by binding to IL-2 receptors. In this specific therapeutic approach, aldesleukin is administered intracavitary (directly into the tumor cavity) alongside autologous LAK cells—patient-derived lymphocytes that have been activated and expanded ex vivo with IL-2. This localized delivery is intended to bypass the blood-brain barrier and stimulate a targeted immune response against primary, recurrent, or refractory brain tumors by enhancing the cytolytic activity of the infused immune cells within the tumor microenvironment.
- Other names
- IL-2IL2IL 2interleukin-2interleukin2interleukin 2LAK cellsautologous lymphokine-activated killer cellsrecombinant human interleukin-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on aldesleukin + lymphokine-activated killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + lymphokine-activated killer cells.